Wet Age-Related Macular Degeneration (AMD) Market And its Growth prospect in the Near Future

1
Wet Age-Related Macular Degeneration Market to
Reach 10.4 Billion by 2024
2
The market is predominantly driven by the
increase in prevalence of AMD, lack of
availability of specific treatment, and surge in
geriatric population, according to PS
Intelligence. Lucentis, Eylea, and Avastin are
the key drugs available globally for the
management of wet AMD. Among these, Eylea is
expected to dominate the market during the
forecast period. Increasing prevalence of AMD and
rise in demand for Eylea are some of the major
factors propelling the demand for this drug in
the wet age-related macular degeneration
market. Based on the route of administration,
the wet age-related macular degeneration market
is bifurcated into intravitreally and
intravenously administered drugs. During the
forecast period, the market is expected to
witness faster growth in the category of drugs
administered through the intravitreal route, with
7.2 CAGR. Access Detailed Report Summary
https//www.psmarketresearch.com/market-analysis/w
et-age-related-macular-degeneration-market

3
Geographically, North America holds the largest
share in the wet age-related macular degeneration
market, with an estimated revenue contribution of
around 3.0 billion in 2018. Rising prevalence of
wet AMD, growing number of drug approvals, and
extensive presence of key players in the region
are the key factors supporting the market growth
in North America. During the forecast period,
the wet age-related macular degeneration market
is expected to witness the fastest growth in
APAC, with 8.8 CAGR. The growth in the APAC wet
age-related macular degeneration industry is
mainly led by the surge in geriatric population,
rise in prevalence of AMD, and medical
reimbursements provided by the government for the
treatment in the region. Request to Get the
Sample Pages at https//www.psmarketresearch.co
m/market-analysis/wet-age-related-macular-degenera
tion-market/report-sample

4
Also, since the treatment of wet AMD is quite
expensive, government in countries, such as South
Korea and Malaysia, have introduced health
insurance plans that cover some of the treatment
cost to reduce the healthcare burden on people.
For instance, under South Koreas universal
government health insurance plan, patients
suffering from wet AMD can receive up to 10
injections of ranibizumab during their lifetime.
Thus, government initiatives in the form of
medical reimbursements are supporting the growth
of the wet age-related macular degeneration
market in the APAC region. The global wet
age-related macular degeneration market is marked
by the presence of several large players, such as
Regeneron Pharmaceuticals Inc., Neurotech
Pharmaceuticals Inc., Ophthotech Corporation,
Kubota Pharmaceutical Holdings Co. Ltd., Gilead
Sciences Inc., Novartis AG, Alimera Sciences
Inc., and Bayer AG.

5
THANK YOU!
For queries, kindly write to
enquiry_at_psmarketresearch.com
GET IN TOUCH
www.psmarketresearch.com
B-13, Sector-2, Noida, U.P.-201301, INDIA Contact
No 91 120 4541 337 US/Canada Toll-Free
1-888-778-7886  
US/Canada Toll-Free 1-888-778-7886